Ariel Perez Perez, MD, discusses key results and clinical implications from a retrospective study of polatuzumab-vedotin plus rituximab with or without bendamustine in relapsed/refractory large B-cell lymphomas.
Ariel Perez Perez, MD
Advertisement
Articles by Ariel Perez Perez, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026
2
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
3
Aglatimagene Besadenovec Plus EBRT Improves Prostate Cancer-Specific DFS
4
Hematologists Highlight Top Data From ASCO 2026
5